ABT Stock Recent News
ABT LATEST HEADLINES
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
RBC Capital has recently adjusted its outlook on Abbott Laboratories (ABT, Financial), increasing its target price from $125 to $130. The firm continues to maintain an "Outperform" rating for the company, indicating a strong confidence in its potential for growth in the market.
Abbott (ABT) closed at $114.63 in the latest trading session, marking a +1.12% move from the prior day.
Abbott Laboratories's ABT MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.
CNBC's Jim Cramer explains why he is keeping an eye on shares of Abbott Labs.
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Abbott (ABT) concluded the recent trading session at $113.64, signifying a +0.07% move from its prior day's close.
A Missouri mother and her lawyers this week will aim to convince a jury that Abbott , Reckitt's Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she says her premature son got from the companies' formulas after he was born at the hospital.